増殖糖尿病網膜症（PDR）は、糖尿病網膜症の中でも最も重篤なタイプです。増殖糖尿病網膜症は、時間の経過とともに網膜の表面にもろい新生血管が形成されることで発症します。これらの異常な血管は出血したり、瘢痕組織を形成したりして重度の視力低下を引き起こすことがあります。発症要因としては、糖尿病、高血圧、高コレステロール、妊娠、タバコの使用などが挙げられます。症状としては、視界に斑点や黒い糸が浮かぶ、視力低下、視界の変動、目のかすみ、色の認識困難などがあります。
目次
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Proliferative Diabetic Retinopathy (PDR) - Overview
Proliferative Diabetic Retinopathy (PDR) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Proliferative Diabetic Retinopathy (PDR) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proliferative Diabetic Retinopathy (PDR) - Companies Involved in Therapeutics Development
Apexian Pharmaceuticals Inc
Boehringer Ingelheim International GmbH
Generium
Kubota Vision Inc
Kuur Therapeutics Ltd
OcuTerra Therapeutics Inc
Oxurion NV
Ribomic Inc
Proliferative Diabetic Retinopathy (PDR) - Drug Profiles
APX-3330 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BI-764524 - Drug Profile
Product Description
Mechanism Of Action
History of Events
brolucizumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
emixustat hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
OTT-166 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
RBM-008 - Drug Profile
Product Description
Mechanism Of Action
History of Events
THR-687 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Proliferative Diabetic Retinopathy (PDR) - Dormant Projects
Proliferative Diabetic Retinopathy (PDR) - Product Development Milestones
Featured News & Press Releases
May 08, 2016: Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic Retinopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Apexian Pharmaceuticals Inc, 2022
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Boehringer Ingelheim International GmbH, 2022
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Generium, 2022
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Kubota Vision Inc, 2022
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Kuur Therapeutics Ltd, 2022
Proliferative Diabetic Retinopathy (PDR) - Pipeline by OcuTerra Therapeutics Inc, 2022
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Oxurion NV, 2022
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Ribomic Inc, 2022
Proliferative Diabetic Retinopathy (PDR) - Dormant Projects, 2022
List of Figures
Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
